PRPH Form 4: CEO Ted Karkus Receives 500,000 Warrants at $0.60
Rhea-AI Filing Summary
ProPhase Labs director and CEO & Chairman Ted Karkus was issued a warrant to purchase 500,000 shares of ProPhase Labs common stock as of 09/09/2025. The warrant has a $0.60 exercise price, a five-year term expiring 09/09/2030, and was issued as consideration tied to a related-party loan dated 06/22/2025. Issuance occurred only after shareholders approved increasing authorized common shares from 50,000,000 to 1,000,000,000 on 09/09/2025. The transaction is reported on Form 4 and the warrant details are described in the company’s Current Report on Form 8-K/A filed 06/26/2025.
Positive
- Warrant issuance is fully disclosed on Form 4 with reference to the related 8-K/A, providing transparency on terms
- Shareholder approval was obtained to increase authorized shares, enabling the company to complete the agreed issuance
Negative
- Related-party transaction: the warrant was issued as consideration for a loan from the CEO & Chairman, which raises governance oversight considerations
- Potential dilution from 500,000 warrants exercisable into common stock at $0.60 through 09/09/2030
Insights
TL;DR Related-party loan resulted in issuance of 500,000 warrants after shareholder approval to increase authorized shares.
The transaction is a clear related-party arrangement: the CEO and Chairman provided a loan to the issuer and received a warrant as consideration contingent on shareholder approval to increase authorized shares. Material governance points include board/officer participation in a financing that created equity-linked consideration and the need for transparent disclosure of the terms in the referenced 8-K/A. Investors should note the direct link between the loan agreement and the equity instrument issuance; this raises standard governance questions about arm’s-length terms and disclosure adequacy, all of which are documented in the filings.
TL;DR 500,000 warrants at $0.60 exercised over five years may create dilution, issued as part of related-party financing.
From a securities perspective the warrant gives the holder the right to acquire 500,000 common shares at $0.60 through 09/09/2030. The issuance followed shareholder approval to expand authorized shares, enabling the company to issue the instrument. The Form 4 references the underlying 8-K/A for full economic terms and confirms direct beneficial ownership post-transaction. The item is transaction-level and routine for insider-financing arrangements; it is material to share count and capitalization but the filings provide the operative dates, exercise price, and expiration explicitly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | warrants | 500,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Warrants issued upon increase in authorized shares being approved by shareholders. The Reporting Person loaned PRPH funds, with a contingency that a warrant to purchase 500,000 shares of the Issuer's common stock at an exercise price of $0.60 per share would be issued if and only if the company's shareholders approved an amendment to the Certificate of Incorporation increasing the authorized shares of common stock from 50,000,000 to 1,000,000,000. Shareholders approved the increase in the authorized shares on September 9, 2025. The Warrant is described in the Issuer's Current Report on Form 8-K/A filed June 26, 2025 (Item 1.01), which states the Warrant has a five-year term. The expiration date shown (09/09/2030) is a five-year term from the issuance date. The Warrant was issued as consideration in connection with a related-party loan agreement between the Issuer and the Reporting Person dated June 22, 2025. See Form 8-K/A filed June 26, 2025 for additional details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
